Why CRISPR Therapeutics Stock Sank 12.5% in November

·2-min read
Why CRISPR Therapeutics Stock Sank 12.5% in November

Shares of CRISPR Therapeutics (NASDAQ: CRSP) sank 12.5% in November, according to data from S&P Global Market Intelligence. The biotech company published better-than-expected third-quarter earnings in the month and provided an update on its product pipeline, but its stock sold off amid bearish momentum for the broader market. Catalysts weighing on the stock market last month included rising Treasury bond yields, ongoing supply-chain issues, and the threat that the emergence of the omicron coronavirus variant would create additional economic disruptions.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting